原创《来氟米特联合缬沙坦治疗糖尿病肾病蛋白尿疗效安全性观察》：本文是一篇关于来氟米特论文范文，可作为相关选题参考,和写作参考文献。
DOI：10.16658/j.cnki.1672-4062.2017.05.017
[摘 要] 目的 探讨来氟米特联合缬沙坦治疗糖尿病肾病蛋白尿的疗效及安全性.方法 纳入该院100例确诊为糖尿病肾病的患者,24 h尿蛋白定量≥1 g/d,随机抽签分为两组,各50例.对照组50例应用常规剂量缬沙坦治疗糖尿病肾病,观察组50例在应用常规剂量缬沙坦的基础上,给予来氟米特联合治疗糖尿病肾病.比较两组患者治疗后3个月疗效,24 h尿蛋白定量、尿素氮、肌酐、超敏C反应蛋白及不良反应发生情况. 结果 观察组总有效率明显高于对照组（P<0.05）.观察组24 h尿蛋白定量、尿素氮、肌酐、超敏C反应蛋白显著低于对照组（P<0.05）.两组胃肠道反应、皮疹、ALT升高、WBC下降的总发生率差异无统计学意义（P>0.05）. 结论 来氟米特联合缬沙坦较单独使用缬沙坦治疗能够更好的治疗糖尿病肾病蛋白尿,且对患者的不良反应较小,因此临床使用来氟米特来氟米特联合缬沙坦治疗糖尿病肾病蛋白尿是一种安全、可行的方法.
[关键词] 来氟米特；糖尿病肾病蛋白尿；疗效；安全性
[中图分类号] R587.1 [文獻标识码] A [文章编号] 1672-4062（2017）03（a）-0017-03
Observation on Curative Effect and Safety of Leflunomide Combined with Valsartan in Treatment of Diabetic Renal Proteinuria
YANG Yuan
Department of Internal Medicine of Nephropathy, Judicial Police officer"s Hospital of Sichuan Province, Chengdu, Sichuan Province, 610000 China
[Abstract] Objective To study the curative effect and safety of leflunomide combined with valsartan in treatment of diabetic renal proteinuria. Methods 100 cases of patients with diabetic nephropathy in our hospital whose 24 h urine protein quantitation≥1 g/d were selected and randomly divided into two groups with 50 cases in each, the control group adopted the routine-dose valsartan, while the observation group adopted the leflunomide on the basis of the control group, and the curative effect in 3 months after treatment, 24 h urine protein quantitation, urea nitrogen, creatinine and hs-CRP an occurrence of adverse reactions were compared between the two groups. Results The total effective rate in the observation group was obviously higher than that in the control group（P<0.05）, and the 24 h urine protein quantitation, urea nitrogen, creatinine and hs-CRP an occurrence of adverse reactions in the observation group were obviously lower than those in the control group（P<0.05）, and there was no obvious difference in the total incidence rate of gastrointestinal reaction, rash, ALT elevation and WBC decrease between the two groups（P>0.05）. Conclusion Leflunomide combined with valsartan in treatment of diabetic renal proteinuria can better treat the diabetic renal proteinuria compared with the single use of valsartan with fewer adverse reactions, therefore, it is a safe and feasible method in clinic.
[Key words] Leflunomide； Diabetic renal proteinuria； Curative effect； Safety
糖尿病肾病是临床上糖尿病患者最常见的并发症之一[1],其主要危害在于该病变极易诱发慢性的微血管病变,若无有效的药物控制,糖尿病肾病会最终发展成为终末期肾病.目前,临床上主要采用缬沙坦等药物控制和治疗糖尿病肾病.有研究证明,单独使用药物治疗的效果缺乏满意度,且不安全因素和不良反应较多[2].而不同药物联合治疗的方法虽在临床得到了试验,但联合用药的疗效及安全性仍有待证实.为此,该研究纳入100例糖尿病肾病的患者,比较2种治疗方法的疗效和安全性,为临床提供参考,现报道如下.
来氟米特论文参考资料：
结论：来氟米特联合缬沙坦治疗糖尿病肾病蛋白尿疗效安全性观察为适合不知如何写来氟米特方面的相关专业大学硕士和本科毕业论文以及关于来氟米特片是激素药吗论文开题报告范文和相关职称论文写作参考文献资料下载。
